Formulated for hypercholesterolemia to manage LDL levels and support cardiovascular health.
Mechanism of Action
Ezetimibe inhibits the absorption of cholesterol from the small intestine by targeting the Niemann-Pick C1-like 1 (NPC1L1) protein. This reduces the amount of dietary and biliary cholesterol reaching the liver, lowering overall serum levels.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
22 hours (half-life)
Contraindications
Active liver disease (when used with statins), Hypersensitivity to ezetimibe
Severe Adverse Events
Rhabdomyolysis, Hepatotoxicity, Pancreatitis — requires immediate medical attention
Common Side Effects
Fatigue, Abdominal pain, Diarrhea
Uncommon Side Effects
Arthralgia, Sinusitis, Elevated liver enzymes
Drug Interactions
Alcohol, Cyclosporine, Fibrates, Cholestyramine
Pregnancy Safety Warnings
FDA Category C: Use only if potential benefit outweighs risk. Breastfeeding: Excreted in animal milk; monitor infant.
Age Restrictions
Safety and efficacy established in pediatric patients 10 years and older.
Information related to Ezetimibe is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
